top of page
  • LinkedIn
  • Twitter

Contact

Careers

News

Biogen looks to expand neuro pipeline via C4, Skyhawk deals

A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.)


For more information visit: www.skyhawktx.com https://www.linkedin.com/company/skyhawk-therapeutics/ https://twitter.com/Skyhawk_Tx


SKYHAWK MEDIA CONTACT: Maura McCarthy maura@skyhawktx.com




bottom of page